Kelly Morgan, MS, CGC, on Pre- and Post-Test Online Education for the Ashkenazi Jewish BRCA Mutation


The MSK expert discussed what pre- and post-test online education consists of in testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers.

In an interview with CancerNetwork, Kelly Morgan, MS, CGC, a genetic counselor at Memorial Sloan Kettering Cancer Center, what pre- and post-test online education consists of in testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system.


This was all through self-motivated enrollment, if you Well, you know, the study was community outreach based, essentially, participant would go online to a portal where they would receive chat bot based education. And that would consist of both text and videos that would cover the information that one might need to make an informed decision about whether or not genetic testing was right for them. And then as an added component, what it meant to be a study participant. So through the combination of the video and the conversational chat bot, participants would learn what they may need to know to choose to participate and then you know, make a decision and move forward and it was all something they could do online from home on their own time, as opposed to say in a clinicians office, but it still had that medical component of the core of the information they may might need.

Yeah, so it was during registration that participants would have the chance to select whether they prefer to receive results from their primary care provider or a study genetic counselor. So if they were to choose a primary care provider, then we as a study team would reach out to the primary care provider share information about what would be involved in the study and disclosing genetic test results to their patients. And they could choose whether or not they wanted to participate. And so for primary care providers who opted in to the study, they would then be responsible for sharing results with their patients and then as a study team, we would also provide support and guidance if any doctors had questions or wanted more information.

Related Videos
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center,
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.